Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in MRNA — Moderna, Inc.

CIK 1423053 MIAMI, FL
Back to MRNA Full portfolio

Position in MRNA

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$24,880,316
+$7,801,773 QoQ
Shares Held
489,770
-15.4% QoQ
Ownership
0.123%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in MRNA Over Time

Shares Held

Position Value (USD)

Derivatives in MRNA

reported options exposure · as of Mar 31, 2026
CallValue
$182,981,600
CallShares
3,602,000
PutValue
$151,058,880
PutShares
2,973,600

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $5,784,241,435 across 374 Biotechnology names. MRNA ranks #49 (0.4% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 INSM
INSMED Inc
 2,182,571 $356,894,009
2 ONC
BeOne Medicines Ltd.
 1,032,298 $306,561,536
3 BMRN
Biomarin Pharmaceutical Inc
 4,512,634 $254,918,694
4 JAZZ
Jazz Pharmaceuticals plc
 1,259,444 $238,097,887
5 MDGL
Madrigal Pharmaceuticals, Inc.
 453,843 $237,573,195
6 BBIO
BridgeBio Pharma, Inc.
 3,173,940 $235,696,783
7 TERN
Terns Pharmaceuticals, Inc.
 3,218,810 $169,695,662
8 PTGX
Protagonist Therapeutics, Inc
 1,551,900 $163,570,260

All Filings in MRNA

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $151,058,880 2,973,600
2026-03-31 $24,880,316 489,770
2026-03-31 $182,981,600 3,602,000
2025-12-31 $203,377,785 6,896,500
2025-12-31 $17,078,543 579,130
2025-12-31 $131,501,808 4,459,200
2025-09-30 $155,623,167 6,024,900
2025-09-30 $166,161,807 6,432,900
2025-09-30 $51,343,091 1,987,731
2025-06-30 $50,619,592 1,834,708
2025-06-30 $129,623,338 4,698,200
2025-06-30 $115,806,266 4,197,400
2025-03-31 $111,455,190 3,931,400
2025-03-31 $49,904,079 1,760,285
2025-03-31 $138,781,755 4,895,300
2024-12-31 $141,916,698 3,413,100
2024-12-31 $142,519,608 3,427,600
2024-12-31 $32,095,269 771,892
2024-09-30 $168,197,744 2,516,800
2024-09-30 $143,771,379 2,151,300
2024-09-30 $16,866,288 252,376
2024-06-30 $212,325,000 1,788,000
2024-06-30 $54,679,150 460,456
2024-06-30 $215,471,875 1,814,500
2024-03-31 $228,699,072 2,146,200
2024-03-31 $29,020,230 272,337
2024-03-31 $193,385,088 1,814,800
2023-12-31 $200,282,355 2,013,900
2023-12-31 $232,623,495 2,339,100
2023-12-31 $53,804,041 541,016
2023-09-30 $52,204,315 505,415
2023-09-30 $288,334,035 2,791,500
2023-09-30 $277,881,087 2,690,300
2023-06-30 $225,698,400 1,857,600
2023-06-30 $12,071,632 99,355
2023-06-30 $207,558,450 1,708,300
2023-03-31 $34,246,035 222,985
2023-03-31 $370,143,158 2,410,100
2023-03-31 $292,539,184 1,904,800
2022-12-31 $771,827,140 4,297,000
2022-12-31 $18,076,597 100,638
2022-12-31 $533,309,742 2,969,100
2022-09-30 $285,987,625 2,418,500
2022-09-30 $243,015,575 2,055,100
2022-09-30 $9,882,980 83,577
2022-06-30 $338,397,365 2,368,900
2022-06-30 $12,993,493 90,959
2022-06-30 $259,601,305 1,817,300
2022-03-31 $640,548,810 3,718,500
2022-03-31 $565,512,354 3,282,900

Report a Problem

Category
Description
Email (optional, for follow-up)